Thursday, January 16, 2014 3:31:04 PM
Thursday, January 16, 2014Looking Ahead: The 2014 PacBio Technology Roadmap
By Jonas Korlach, Chief Scientific Officer
2013 was an eventful and exciting year for PacBio. As I described in the 2013 roadmap post a year ago, we have applied numerous improvements to SMRT® Sequencing, resulting in longer read lengths, greater sequencing throughput, new and improved data-analysis methods, and more efficient workflows. We are very pleased that these advances resulted in so many publications, conference presentations, and social media contributions, with the number of peer-reviewed scientific publications from the scientific community now exceeding 100. On behalf of all of us at Pacific Biosciences, I would like to express my heartfelt gratitude to the scientific community for their time and efforts to apply PacBio® sequencing to solve their research questions, and for their invaluable help to drive applications for SMRT Sequencing forward. We all very much look forward to working together with you in 2014!
As with any relatively new technology, significant improvement and optimization potential exists upon the initial introduction. SMRT Sequencing is no exception to this, and we intend to continue to leverage this potential to the benefit of the research community. Consistent with the technology improvements in previous years, we are targeting another ~4-fold increase in the throughput per SMRT Cell to achieve average read lengths greater than 10-15 kb and overall sequence data outputs in excess of 1 Gb per SMRT Cell, while at the same time preserving SMRT Sequencing's high consensus accuracy, lack of sequencing bias, and ability to detect many epigenetic base modifications. The improvements will be accomplished by a combination of sequencing chemistry upgrades through polymerase and nucleotide engineering, improvements in the polymerase loading efficiency, and software upgrades.
In addition to the sequencing process itself, we will continue to develop improvements for the other two aspects relevant to sequencing. For library preparation, more streamlined protocols will become available, including automated library preparation methods on liquid handling robots. Further, we are developing improved protocols that better ensure the integrity of large inserts (10-20 kb) during the generation of high-quality, long-insert DNA libraries. In addition, protocols with a further reduction in the amount of DNA input, as well as improved barcoding and multiplexing solutions, will become available. With regard to data analysis, our ongoing progress to support and accelerate the analysis of larger genomes, including the human genome, will continue, with improvements to the speed of components such as our mapping tool BLASR and consensus caller Quiver. New methods achieving the assemblies and appropriate representation of organisms with diploid genomes will become available, thereby providing a significant advance in the genetic characterization of virtually all higher organisms, and their corresponding heterozygosity and structural genetic variation. Our Iso-Seq application for the analysis of full-length transcripts and splice isoforms will become more streamlined and include a graphical interface for greater ease of use.
We are indebted to the community for helping with the development of new sample preparation methods and analysis tools for these and many other application spaces, and we anticipate a continuation of these very important contributions. We will continue to release new data sets to the public as we have done in the past, e.g. the Arabidopsis de novo assembly, the long-read human genome dataset for structural variation, the MCF7 Iso-Seq dataset, bacterial methylomes, and the recent Drosophila de novo assembly, to provide the scientific community with examples of what value PacBio data bring to the characterization of the genome, epigenome, and transcriptome of the organism under study, and to help researchers design their own studies.
I am very excited about the prospects for this coming year, and wish you the best of success in your research! http://blog.pacificbiosciences.com/2014/01/looking-ahead-2014-pacbio-technology.html
Recent PACB News
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases • PR Newswire (US) • 05/15/2024 01:45:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:33:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:21:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:12:15 PM
- PacBio Announces First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:05:00 PM
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM